Glucagon-like Peptide 1 Receptor Agonists

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Texas Vendor Drug Program formulary coverage.

• Revision history
  • October 21, 2022; September 2020; September 2018; September 2016; June 2015; October 2013; December 2011; February 2010; January 2010; August 2006; May 2006. 
• Initially developed
  • Feb. 2006